X
Xalud Therapeutics
Discovers, develops, and provides novel treatments for chronic inflammatory diseases that can dramatically improve the health and quality of life for millions of suffering patients
About Xalud Therapeutics
Xalud Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neuroinflammatory diseases and inflammatory joint disorders such as osteoarthritis and rheumatoid arthritis. The company specializes in non-opioid gene therapy solutions aimed at alleviating chronic pain by rebalancing pain signals. Xalud's core technology, developed by Dr. Linda Watkins at the University of Colorado, Boulder, targets glial cells to modulate pain pathways effectively. The company primarily serves patients suffering from chronic pain conditions and inflammatory diseases, offering a promising alternative to traditional opioid treatments. Xalud operates in the biopharmaceutical market, leveraging cutting-edge gene therapy techniques to create long-lasting pain relief solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary therapies. Revenue is generated through partnerships, investments, and future sales of approved treatments.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2021 | $30M | $120M | PBM Capital Group | — |
| EARLY VCOther financing | Mar 2020 | $5M | $20M | Undisclosed | — |
Growth signals
Latest recorded traffic for Xalud Therapeutics is 1.8K monthly website visits, up 480.6% over the last three months. Xalud Therapeutics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xalud Therapeutics in the New York City ecosystem
The Xalud Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
US Department of War
National Institute of Neurological Disorders and Stroke
US Department of Health and Human Services
Series B and later1 investor entered at this stage
- PGPBM Capital Group
Other known investors1 additional known investor
University of Colorado Boulder
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xalud Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xalud Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










